The dose of OPV, given at birth, in case of institutional deliveries is –
I remember that the standard schedule for OPV includes a birth dose, which is given to newborns. But wait, the options here are missing, so I need to be careful. From what I know, the World Health Organization (WHO) recommends a birth dose of OPV to protect against early polio infection. The usual dose is a 0.5 ml oral dose. However, I should verify if there's a difference between home and institutional deliveries. Maybe the dose is the same regardless, but the context here is institutional.
Wait, in some cases, especially in high-risk areas, an additional dose might be given. But the standard protocol for the birth dose is 0.5 ml. Let me check if there's any variation. No, I think the dose remains 0.5 ml whether it's given at home or in a facility. The key point is that the birth dose is part of the routine immunization schedule. So the correct answer should be 0.5 ml. The other options might be different volumes like 1 ml or 0.1 ml, which are incorrect. Also, sometimes confusion might arise with other vaccines like BCG or the hepatitis B vaccine, but their doses are different. For example, BCG is given as a single dose but in a different volume. So the key here is to remember the specific dose for OPV at birth, which is 0.5 ml. The clinical pearl here is that the birth dose of OPV is 0.5 ml, and it's crucial for early protection against polio. The user might be testing if the student knows the exact volume and the context of institutional delivery, which doesn't change the dose. So the correct answer is 0.5 ml, which would correspond to one of the options provided in the original question.
**Core Concept**
The question assesses knowledge of the **Oral Polio Vaccine (OPV) birth dose**, a critical component of global polio eradication strategies. The **0.5 ml dose** is standardized globally for all institutional deliveries to ensure rapid immunity against poliovirus in newborns.
**Why the Correct Answer is Right**
The **0.5 ml dose of OPV** is administered at birth in institutional settings to induce mucosal immunity via the intestinal tract, the primary site of poliovirus replication. This dose contains **live attenuated poliovirus strains (Sabin strains)** that replicate locally without causing disease, priming the immune system. It is universally recommended by WHO for all newborns, regardless of delivery setting, to prevent early transmission and paralytic disease.
**Why Each Wrong Option is Incorrect**
**Option A:** 0.1 ml is too low to achieve seroconversion and is not a WHO-recommended dose.
**Option B:** 1.0 ml exceeds the required volume and risks unnecessary viral shedding without clinical benefit.
**Option C:** 2.0 ml is erroneous and could lead to adverse effects due to excessive viral load.
**Clinical Pearl / High-Yield Fact**
The **birth dose